262 related articles for article (PubMed ID: 34312021)
1. Immunotherapy and Systemic Therapy in Metastatic/Recurrent Endometrial and Cervical Cancers.
Lima J; Ali Z; Banerjee S
Clin Oncol (R Coll Radiol); 2021 Sep; 33(9):608-615. PubMed ID: 34312021
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Efficacy and Adverse Events After Second Immunotherapy Exposure in Endometrial and Cervical Carcinoma.
Morton M; Marcu I; Levine M; Cosgrove C; Backes F; O'Malley D; Chambers L
Obstet Gynecol; 2023 Aug; 142(2):360-363. PubMed ID: 37411031
[TBL] [Abstract][Full Text] [Related]
3. Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer.
Mutlu L; Tymon-Rosario J; Harold J; Menderes G
Expert Rev Anticancer Ther; 2022 Jun; 22(6):633-645. PubMed ID: 35533682
[TBL] [Abstract][Full Text] [Related]
4. Immuno-oncology for Gynecologic Malignancies.
How J; Patel A; Jazaeri A
Adv Exp Med Biol; 2020; 1244():149-182. PubMed ID: 32301014
[TBL] [Abstract][Full Text] [Related]
5. Updates on systemic therapy for cervical cancer.
Gopu P; Antony F; Cyriac S; Karakasis K; Oza AM
Indian J Med Res; 2021 Aug; 154(2):293-302. PubMed ID: 35295013
[TBL] [Abstract][Full Text] [Related]
6. Changing paradigms in the systemic treatment of advanced cervical cancer.
Pfaendler KS; Tewari KS
Am J Obstet Gynecol; 2016 Jan; 214(1):22-30. PubMed ID: 26212178
[TBL] [Abstract][Full Text] [Related]
7. Novel Therapies in Gynecologic Cancer.
Bejar FG; Oaknin A; Williamson C; Mayadev J; Peters PN; Secord AA; Wield AM; Coffman LG
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-17. PubMed ID: 35594502
[TBL] [Abstract][Full Text] [Related]
8. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
9. [Targeted therapy in locally and metastatic recurrent cervical cancers].
Geiss R; De La Motte Rouge T; Dubot C; Leary A; Lhommé C; Pautier P; Scholl S; Rodrigues MJ
Bull Cancer; 2014; 101(7-8):748-55. PubMed ID: 25091657
[TBL] [Abstract][Full Text] [Related]
10. Outcome of patients with local recurrent gynecologic malignancies after resection combined with intraoperative electron radiation therapy (IOERT).
Arians N; Foerster R; Rom J; Uhl M; Roeder F; Debus J; Lindel K
Radiat Oncol; 2016 Mar; 11():44. PubMed ID: 26988089
[TBL] [Abstract][Full Text] [Related]
11. Immuno-Oncology for Gynecologic Malignancies.
How JA; Patel A; Jazaeri AA
Adv Exp Med Biol; 2021; 1342():193-232. PubMed ID: 34972966
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.
Ventriglia J; Paciolla I; Pisano C; Cecere SC; Di Napoli M; Tambaro R; Califano D; Losito S; Scognamiglio G; Setola SV; Arenare L; Pignata S; Della Pepa C
Cancer Treat Rev; 2017 Sep; 59():109-116. PubMed ID: 28800469
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF; Farinas-Madrid L; Oaknin A
Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
[TBL] [Abstract][Full Text] [Related]
14. Recurrent or primary metastatic cervical cancer: current and future treatments.
Gennigens C; Jerusalem G; Lapaille L; De Cuypere M; Streel S; Kridelka F; Ray-Coquard I
ESMO Open; 2022 Oct; 7(5):100579. PubMed ID: 36108558
[TBL] [Abstract][Full Text] [Related]
15. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer.
Post CCB; Westermann AM; Bosse T; Creutzberg CL; Kroep JR
Crit Rev Oncol Hematol; 2020 Aug; 152():102973. PubMed ID: 32497971
[TBL] [Abstract][Full Text] [Related]
16. Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives.
Giudice E; Mirza MR; Lorusso D
Curr Oncol Rep; 2023 Nov; 25(11):1307-1326. PubMed ID: 37870697
[TBL] [Abstract][Full Text] [Related]
17. Optimizing immunotherapy for gynecologic cancers.
Rubinstein MM; Makker V
Curr Opin Obstet Gynecol; 2020 Feb; 32(1):1-8. PubMed ID: 31833942
[TBL] [Abstract][Full Text] [Related]
18. Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors.
Lainé A; Gonzalez-Lopez AM; Hasan U; Ohkuma R; Ray-Coquard I
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046702
[TBL] [Abstract][Full Text] [Related]
19. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.
Monk BJ; Enomoto T; Kast WM; McCormack M; Tan DSP; Wu X; González-Martín A
Cancer Treat Rev; 2022 May; 106():102385. PubMed ID: 35413489
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer.
McLachlan J; Boussios S; Okines A; Glaessgen D; Bodlar S; Kalaitzaki R; Taylor A; Lalondrelle S; Gore M; Kaye S; Banerjee S
Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):153-160. PubMed ID: 27838135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
